Yes, bupropion can be prescribed as an antidepressant for appropriate adult patients
Bupropion is FDA-approved as an antidepressant and is effective for treating major depressive disorder at doses of 300 mg daily, with proven efficacy for long-term treatment of recurrent major depression 1, 2. It represents a valid first-line antidepressant option, particularly for patients who may benefit from its unique side effect profile.
Key Prescribing Considerations
Absolute Contraindications - Do Not Prescribe If:
- Seizure disorder or epilepsy (current or past history) 2
- Eating disorders (anorexia nervosa or bulimia - current or prior diagnosis) 2
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs 2
- MAOI use within 14 days 2
- Known hypersensitivity to bupropion 2
Dosing Algorithm
Standard titration for depression:
- Start: 150 mg once daily in the morning
- After 3 days: Increase to 150 mg twice daily (if tolerated)
- Maximum: 300 mg per day for sustained-release formulations 2
Dose adjustments:
- Renal impairment (GFR <90 mL/min): Reduce dose and/or frequency 2
- Moderate-severe hepatic impairment: Maximum 150 mg daily 2
Comparative Efficacy
The 2008 American College of Physicians guideline found that second-generation antidepressants, including bupropion, do not differ significantly in efficacy for major depressive disorder 3. Selection should be based on adverse effect profiles, cost, and patient preferences 3. A 2023 systematic review confirmed that bupropion demonstrates similar efficacy to SSRIs across multiple outcomes 4.
Unique Advantages
Bupropion is particularly appropriate for patients with:
- Comorbid depression and desire to quit smoking - it's FDA-approved for both indications 5, 1
- Sexual dysfunction concerns - bupropion has significantly lower rates of sexual adverse effects compared to SSRIs like fluoxetine, sertraline, or paroxetine 3
- Concerns about weight gain - unlike many antidepressants, bupropion is associated with weight loss rather than gain 6, 1
- Comorbid depression and obesity - the naltrexone-bupropion combination is reasonable to prioritize for appropriate patients with depressed mood 1
- Fatigue or apathy - bupropion tends to be activating rather than sedating 7
Critical Safety Monitoring
Seizure risk management:
- The seizure rate at therapeutic doses (≤300 mg/day) is 0.06-0.10%, comparable to other antidepressants 8
- Risk increases with doses >450 mg/day 2
- Use caution with factors that lower seizure threshold: head injury, CNS tumor, concurrent medications that lower seizure threshold 2
Neuropsychiatric monitoring:
- Monitor for suicidal thoughts/behaviors, especially in patients <24 years old, particularly during the first 1-2 months 3, 2
- Assess within 1-2 weeks of initiation 3
- Watch for agitation, irritability, unusual behavior changes, mania, delusions, hallucinations 2
Cardiovascular monitoring:
Response Assessment
Timeline for efficacy:
- Initial improvement: 1-2 weeks 7, 9
- Full therapeutic effect: 4-6 weeks 9, 10
- If inadequate response at 6-8 weeks, modify treatment 3
Common Pitfalls to Avoid
- Do not combine with MAOIs - allow 14-day washout period 2
- Do not abruptly discontinue in patients on chronic benzodiazepines or alcohol - this precipitates withdrawal and increases seizure risk 2
- Do not prescribe to patients with brain metastases - contraindicated due to seizure risk 5
- Avoid late-day dosing - second dose should be before 3 PM to minimize insomnia 7, 2
- Do not exceed maximum doses - seizure risk increases substantially above 450 mg/day for immediate-release or 400 mg/day for sustained-release 2
Drug Interactions
- Strong CYP2D6 inhibitor - use caution with drugs metabolized by this pathway 10
- Do not use with tamoxifen - bupropion may reduce tamoxifen efficacy 5
- Caution with other medications that lower seizure threshold 2
Special Populations
Pregnancy/breastfeeding:
- Discuss risks with patient 2
- Consider pregnancy registry enrollment (1-844-405-6185) 2
- Passes into breast milk - discuss feeding options 2
Diabetes:
- Monitor blood sugar closely in diabetic patients on insulin or oral hypoglycemics 2